Form 4: Ligand Pharmaceuticals Director Sells Shares Under Pre-Arranged Trading Plan

Ligand Pharmaceuticals Inc. Director John W. Kozarich sold 934 shares of common stock for $125 per share on July 10, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• John W. Kozarich, a Director of Ligand Pharmaceuticals Inc. (LGND), reported a sale of common stock.
• The transaction involved the disposition of 934 shares of common stock.
• The shares were sold at a price of $125 per share.
• The transaction date was July 10, 2025.
• Following this transaction, John W. Kozarich beneficially owns 46,456 shares of common stock directly.
• The sale was executed pursuant to a written trading plan adopted by Mr. Kozarich on March 07, 2025, in accordance with Rule 10b5-1.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns about opportunistic selling and indicates a planned diversification or liquidity event rather than a reaction to adverse company news.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a reaction to immediate company news, which enhances transparency and reduces concerns about opportunistic insider trading.

Negatives

• An insider sale, even if pre-planned, represents a reduction in direct ownership by a company director.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it is a report of a past transaction.

Management Comments

• The transaction reported was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information related to broader industry trends or competitive landscape.

Comparison to Industry Standards

• This document reports a standard insider transaction (Form 4) and does not contain information that allows for a comparison of company performance or results against global benchmarks or specific comparable companies/projects.

Related Party Transactions

• The document reports an insider stock sale, which is a transaction involving a related party (a director), but no other specific related party dealings are disclosed beyond this.

Stakeholder Impact

• Shareholders: The sale by a director slightly reduces insider ownership, which could be perceived as a minor negative, though the 10b5-1 plan context lessens this impact.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Sale, John W. Kozarich, Director, Beneficial Ownership, Rule 10b5-1, Stock Transaction